peptides for FAQ

Yes, but timing is critical. Start BPC-157 3–5 days before surgery at 350–500 mcg daily to prime vascular networks and fibroblast activity. Resume immediately post-op (within 12–24 hours) and continue for 4–6 weeks. Studies in post-surgical tendon repair found pre-operative BPC-157 reduced adhesion formation by 30–40% and improved tensile strength at 6 weeks by 25%. The peptide doesn't interfere with anesthesia or wound closure. It accelerates the repair phase, not the inflammatory phase.

BPC-157's short half-life (~4 hours) means missing 2–3 days reduces tissue concentrations significantly. Resume at standard dose when you return, don't attempt to 'catch up' with double doses. TB-500's longer half-life (7–10 days) provides more flexibility: missing a single dose shifts the schedule but doesn't drastically reduce effectiveness. For travel periods longer than one week, consider pausing the protocol entirely and restarting with a fresh vial when you return. Interrupted dosing with degraded peptides (from inadequate travel refrigeration) is worse than clean breaks in the protocol.

Discard it immediately. Cloudiness, discoloration, or particulate matter in a reconstituted peptide solution indicates protein aggregation or contamination. Both render the solution unusable. Properly reconstituted peptides should be clear and colorless (or match the appearance described in the product specification). Aggregation occurs when peptides are exposed to temperatures above 8°C for extended periods, when bacteriostatic water is contaminated, or when the lyophilized powder was stored incorrectly before reconstitution. Do not attempt to filter or clarify the solution. Aggregated proteins cannot be restored to functional form. Temperature discipline during storage and reconstitution is non-negotiable for maintaining peptide integrity.

Administer 250–500 micrograms subcutaneously near the injured pulley daily within 48 hours of injury onset. Early intervention maximizes angiogenesis during the acute inflammatory phase when VEGF receptors are upregulated. Combine with complete rest from crimp positions for the first 7–10 days. Peptides accelerate healing but don't eliminate the need for mechanical offloading. Most climbers report pain reduction within 10–14 days and return to low-intensity training at week 3–4 instead of the typical 6–8 week timeline.

Coordinate timing with your surgical team. Most research protocols begin peptides 7–10 days post-surgery once initial surgical inflammation has peaked and resolved. Starting too early can theoretically increase swelling at the surgical site; starting after week 2–3 means you've missed the critical proliferative phase of healing. The ideal window is when surgical drains are removed and active range-of-motion exercises begin. TB-500's anti-inflammatory properties can complement NSAIDs, but don't use it as a replacement without medical guidance. Surgical pain management serves a protective function.

Administer TB-500 immediately. The proliferative phase (days 3–7) is when this peptide shows peak efficacy for soft tissue regeneration. You've missed the optimal window for BPC-157's angiogenic effects, but TB-500 still accelerates collagen deposition and reduces pain during the critical healing phase. Research protocols show benefit up to day 5 post-surgery.

Seek emergency medical evaluation first. Sudden sensorineural hearing loss is a medical urgency requiring audiometric testing and often immediate corticosteroid treatment within 72 hours. Thymalin or other peptides are adjunctive considerations, not replacements for standard care. If corticosteroids fail or are contraindicated, discussing immune-modulating peptides with an otolaryngologist familiar with research protocols is reasonable, but timing matters. Most animal studies show benefit only when administered within 48 hours of onset.

Reassess your ergonomic setup first. If you're still typing 8+ hours daily without wrist support, no peptide will outpace the ongoing damage. BPC-157's benefit is conditional on reducing the repetitive strain causing the inflammation. If ergonomics are optimised and symptoms persist, consider adding TB-500 to address nerve compression directly. Some cases involve significant median nerve demyelination that requires 8–12 weeks of combined therapy before measurable improvement in nerve conduction studies.

Yes. Symptom resolution doesn't mean mucosal repair is complete. Administer BPC-157 at 250mcg twice daily for 5 days starting on day 2 to accelerate epithelial healing and prevent the two-week recovery tail caused by incomplete villous regeneration. Studies show mucosal damage persists 72–96 hours after nausea and diarrhea stop.

Limited benefit. Possibly none. NAD+ precursors like NMN support ALDH2 enzyme function during acetaldehyde production, which occurs while alcohol is being metabolized (0–6 hours post-consumption depending on intake volume). By the time you wake up hungover, acetaldehyde levels have already peaked and dropped. Administering NMN at that point addresses a metabolic bottleneck that no longer exists. Post-drinking NMN may support general cellular recovery via mitochondrial NAD+ restoration, but this is mechanistically separate from hangover symptom reduction.

Dihexa addresses synaptic connectivity, not photoreceptor regeneration. If central scotoma is due to geographic atrophy (dead photoreceptors in the macula), enhancing synaptic density in remaining peripheral vision pathways won't restore central vision. Dihexa might theoretically improve visual processing efficiency in intact areas, but no clinical data supports this application. It's speculative and not a substitute for low-vision rehabilitation.

Preventative use lacks research support. Peptides function by modulating healing pathways that activate in response to injury, not by strengthening tissue in advance. There's no evidence that prophylactic BPC-157 or TB-500 administration reduces injury incidence in uninjured tissue. The better approach: address mechanical risk factors (quad/hamstring strength ratios, ankle dorsiflexion range) and equipment setup (binding DIN settings, boot stiffness) that actually predict injury occurrence. Peptides are repair tools, not prevention tools. If you're recovering from a prior season's injury and want to ensure full healing before the next season, complete a full peptide protocol during the off-season (6–8 weeks minimum), then allow 4–6 weeks of peptide-free tissue remodeling before returning to impact loading. The tissue strength gains from peptide-assisted healing need time to stabilize through normal mechanical loading without the peptide stimulus. The decision to use peptides for skiing injury recovery comes down to risk tolerance and access to quality compounds. If you're working with a sports medicine physician familiar with peptide research and have access to third-party tested peptides from a verified supplier like Real Peptides, the risk-benefit ratio shifts favourably for significant soft tissue injuries. Particularly those with documented poor healing rates like rotator cuff tears or hamstring avulsions. For minor strains and sprains that resolve within 4–6 weeks with standard care, the added complexity and cost likely isn't justified. The compounds work, but they're tools for specific scenarios, not universal solutions.

Peptides can't reverse established recession caused by bone loss, but they may slow progression and improve tissue quality. BPC-157 and thymosin beta-4 stimulate fibroblast activity and collagen deposition, which thickens existing gingival tissue and improves keratinization. The outer protective layer. A 2023 case series in the Journal of Esthetic and Restorative Dentistry reported using BPC-157 gel applied nightly for 12 weeks in patients with mild-to-moderate recession. Mean gingival thickness increased by 0.4mm, and recession depth stabilized with no further loss at one-year follow-up. This isn't tissue regeneration at the bone level, but it's meaningful improvement in tissue resilience.

Administer BPC-157 at 250–500 mcg subcutaneously twice daily, injected near the affected shoulder or systemically, for 4–6 weeks. The peptide upregulates growth factor receptors in damaged tendon tissue, promoting angiogenesis and collagen remodeling that passive rest and NSAIDs don't trigger. Pair this with eccentric loading exercises (3 sets of 12 reps, 2–3 times weekly) to stimulate mechanical signaling pathways that complement peptide-driven repair. Most athletes report functional improvement within 10–14 days and structural healing markers on ultrasound by week 4–6.

Start during the inflammatory phase. Within 48–72 hours post-injury. BPC-157 and TB-500 don't suppress inflammation entirely; they modulate it toward resolution while simultaneously initiating proliferative processes. Delaying peptide administration until week two means missing the critical window when fibroblast recruitment and angiogenesis determine scar tissue quality versus functional tissue restoration. Research models administering BPC-157 within 24 hours of induced Achilles tendon rupture showed superior biomechanical strength at 14 days compared to delayed administration groups.

KPV in enteric-coated oral formulations delivers localized anti-inflammatory effects directly to intestinal tissue. Bioavailability is lower than subcutaneous (approximately 30–40%), but sufficient for mild-to-moderate cases. BPC-157 resists gastric degradation and shows partial efficacy when taken orally at 2–3× standard subcutaneous doses, though research on oral bioavailability remains limited.

Add KPV to your protocol. Reflux-induced laryngeal damage creates a vicious cycle: acid erodes the epithelial barrier, allowing deeper tissue damage, which triggers more inflammation and slows healing. KPV restores tight junction proteins (occludin, claudin) that seal the epithelial barrier, reducing acid penetration while BPC-157 repairs underlying structural damage. Dosing: 500 mcg KPV daily alongside standard BPC-157 protocol.

Start Selank immediately at 300–600mcg daily and use strategic light exposure during the flight. You've lost the window for pre-shift pineal priming with Thymalin or Epitalon, so focus on cortisol management and light-based SCN cueing. Wear blue-blocking glasses during the flight's sleep window (aligned with night at your destination), remove them during destination daytime, and dose Selank in the morning to blunt the cortisol spike that occurs when you force wakefulness against your internal clock.

Mild redness at the injection site within 1–2cm is normal histamine response and resolves in 24 hours. Spreading redness beyond 3cm, warmth, or purulent discharge indicates potential bacterial contamination or endotoxin reaction. Stop administration immediately. This underscores why third-party endotoxin testing matters: bacterial lipopolysaccharides from impure synthesis trigger systemic inflammation that mimics infection.

Post-refractive surgery neurotrophic keratopathy. Corneal nerve damage causing severe dry eye symptoms disproportionate to clinical signs. Responds poorly to standard therapy because the pathology is neurogenic, not inflammatory. Thymosin Beta-4 promotes corneal nerve regeneration through neurotrophin upregulation (NGF, BDNF) demonstrated in animal models of corneal denervation injury. Anecdotal reports from ophthalmologists using compounded Tβ4 in post-LASIK patients describe symptom resolution within 4–8 weeks where previous therapies (including autologous serum) provided minimal relief. No controlled trials exist for this specific indication, but the mechanistic rationale is sound: if the primary deficit is nerve function rather than tear production or inflammation, a neurotropic peptide addresses the root cause.